Blog

Giovanni Marchegiani: Perioperative modified FOLFIRINOX for pancreas cancer

Photo of Michael Cecchini taken from medicine.yale.edu

Jun 24, 2024, 22:56

Giovanni Marchegiani: Perioperative modified FOLFIRINOX for pancreas cancer

Giovanni Marchegiani, Pancreas Surgeon at The University of Padua, made the following post on X:

“Perioperative modified FOLFIRINOX for resectable pancreas cancer

Non randomized trial 46 pts
72% underwent surgery
12 months PFS 67%
Postoperative ctDNA positivity was strongly associated with recurrence.”

Syed A. Ahmad, Director at University of Cincinnati Cancer Center & Chief of Surgical Oncology at University of Cincinnati, retweeted the post, adding the following:

“Interesting results. Similar to our SWOG Cancer Research Network 1505 trial with % completing upfront tx, low % of adj, and getting surgery but sig longer mOS (37.2 v. 22.4 mo). Wonder if pts getting surgery off protocol and included in ITT affected results? Will need to read paper.”

Read further.
Source: Giovanni Marchegiani/X and Syed A. Ahmad/X
.

cancer cancer recurrence cancer treatment chemotherapy ctDNA Giovanni Marchegiani Michael Cecchini modified FOLFIRINOX OncoDaily Oncology oncology research pancreas cancer Pancreatic Cancer perioperative FOLFIRINOX PFS resectable pancreas cancer surgery surgical oncology SWOG 1505 trial SWOG Cancer Research Network Syed A. Ahmad University of Cincinnati Cancer Center University of Padua

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage